
An announcement from Standard BioTools ( ($LAB) ) is now available. On June 6, 2026, Standard BioTools entered an agreement with Treeline Biosciences and Siri Merger Sub for a merger
Compare up to 40 stocks
Compared Stocks: 2 / 40
| Name | Price | % Change | |
|---|---|---|---|
| $0.57 | -56.53% | ||
| $137.81 | +91.86% |

An announcement from Standard BioTools ( ($LAB) ) is now available. On June 6, 2026, Standard BioTools entered an agreement with Treeline Biosciences and Siri Merger Sub for a merger

Mesa Laboratories (($MLAB)) has held its Q2 earnings call. Read on for the main highlights of the call. Mesa Laboratories’ latest earnings call carried a broadly positive tone, highlighting faster

Reports Q2 revenue $62.34M, consensus $62.2M. “Our second quarter showed the progress we are making and the work that remains. SDC is shipping more reliably on most of its product

Sees FY27 adjusted EBITDA $66M-$68M. The company said, “Fiscal year 2027 adjusted EBITDA guidance compares with adjusted EBITDA of $62,969 for fiscal year 2026, an increase of approximately 5% to

Jefferies raised the firm’s price target on Mesa Labs (MLAB) to $150 from $125 and keeps a Buy rating on the shares. 2027 revenue guidance of $250-$255M, or flat to

Standard Biotools Inc (LAB) is scheduled to report 3rd quarter earnings on 11/10/2026. Regarding Q3 estimates, Wall Street analysts expect Standard Biotools Inc to post earnings of -$0.02 per share.

Mesa Laboratories (MLAB) is scheduled to report 2nd quarter earnings on 11/09/2026, after the market closes. Regarding Q2 estimates, Wall Street analysts expect Mesa Laboratories to post earnings of $2.29

Standard BioTools ( ($LAB) ) has shared an announcement. On November 3, 2026, ARCHIMED and Standard BioTools completed the sale of Standard BioTools’ Microfluidics business to ARCHIMED. The business began

Mesa Laboratories ( ($MLAB) ) has shared an announcement. On October 6, 2026, Mesa Laboratories’ board approved a global restructuring and savings plan aimed at sharpening the focus of its

Mesa Labs (MLAB) announced a savings plan expected to reduce annualized operating costs by approximately $9.3M. The plan consists of a global restructuring program, a reduction in its San Diego,
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 8, 2027TBA | $756.52M | $3.02 | $65.15M | -0.17 | 113.51 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.